We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




POC Tests Represent Significant Share of World IVD Market

By LabMedica International staff writers
Posted on 25 Jan 2011
The market for point-of-care (POC) tests has almost doubled in size from 2003 to 2009. More...
With the ability to help reduce healthcare costs while simultaneously improving patient care, point-of-care (POC) tests represent a significant and growing share of the world in vitro diagnostics (IVD) market.

The growth in POC sales, which is projected to increase by 6% annually through 2014, is largely related to significant increases in glucose self-testing of diabetics, and to various professional test segments including critical care and cardiac markers. Other contributing factors include the globalization of infectious diseases with the associated public health issues, and the need to monitor an increasingly larger group of people with chronic diseases such as cardiovascular disease, arthritis, and cancer.

In a new report, Kalorama Information (Rockville, MD, USA), a healthcare market research publisher, valued the market for combined over the counter (OTC) and professional applications of POC testing at US$13.3 billion worldwide in 2009.

Although POC tests (with the exception of the diabetes segment) have not achieved the 15% to 20% market growth predicted in the late 1990s, they have made a significant contribution to patient care. The total POC testing market has increased its market share in the United States and Europe from 25% of the IVD market in 2003 to 30% in 2009.

"As the largest single market for IVD and POC products, the U.S. has an enormous impact on how the rapid test industry develops," says Shara Rosen, Kalorama Information's lead diagnostics analyst and author of the report. "Managed care's obsession with cost reductions is pushing the need for decentralized testing in the home, at the bedside, and in the physician's office."

A different set of companies is active in each sub-segment of the highly diversified market for POC tests. More than 70 companies are active in POC markets, but with successive rounds of market consolidation and the emergence of Alere (Waltham, MA. USA), formerly Inverness Medical Innovations, as a major POC vendor, Kalorama estimates that 27 companies held 94% of the world market for POC tests in 2009.

Including details of the technologies and trends in decentralized testing, Kalorama Information's report specially focuses on the economics of rapid test use in physicians' offices, hospital critical care units, and emergency medicine and how it will impact healthcare.
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services.

Related Links:

Kalorama Information
Alere



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: LiDia-SEQ aims to deliver near-patient NGS testing capabilities to hospitals, labs and clinics (Photo courtesy of DNAe)

World's First NGS-Based Diagnostic Platform Fully Automates Sample-To-Result Process Within Single Device

Rapid point-of-need diagnostics are of critical need, especially in the areas of infectious disease and cancer testing and monitoring. Now, a direct-from-specimen platform that performs genomic analysis... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: The AI tool advances precision diagnostics by linking genetic mutations directly to disease types (Photo courtesy of Shutterstock)

AI Tool Simultaneously Identifies Genetic Mutations and Disease Type

Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.